Market Closed -
Hong Kong S.E.
09:08:20 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
18.82
HKD
|
+2.51%
|
|
+14.06%
|
-20.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11,730
|
62,629
|
53,868
|
24,455
|
11,353
|
7,950
|
-
|
-
|
Enterprise Value (EV)
1 |
11,142
|
58,324
|
49,253
|
24,455
|
11,353
|
7,734
|
7,080
|
7,017
|
P/E ratio
|
-74.8
x
|
-86.4
x
|
19
x
|
-16
x
|
-3.65
x
|
-12.3
x
|
-120
x
|
12.7
x
|
Yield
|
-
|
-
|
0.54%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
3,377
x
|
12.5
x
|
23.6
x
|
31.8
x
|
9.27
x
|
6.05
x
|
4.06
x
|
EV / Revenue
|
-
|
3,145
x
|
11.5
x
|
23.6
x
|
31.8
x
|
9.02
x
|
5.39
x
|
3.58
x
|
EV / EBITDA
|
-62.8
x
|
-158
x
|
24.4
x
|
-24.6
x
|
-7.01
x
|
-48.6
x
|
53.4
x
|
8.37
x
|
EV / FCF
|
-39.8
x
|
-78.9
x
|
58.2
x
|
-8.36
x
|
-7.48
x
|
-12.9
x
|
-23.1
x
|
17.7
x
|
FCF Yield
|
-2.52%
|
-1.27%
|
1.72%
|
-12%
|
-13.4%
|
-7.74%
|
-4.34%
|
5.66%
|
Price to Book
|
7.28
x
|
6.06
x
|
4.54
x
|
1.97
x
|
1
x
|
0.88
x
|
0.86
x
|
0.82
x
|
Nbr of stocks (in thousands)
|
222,650
|
247,450
|
247,450
|
246,766
|
246,766
|
247,044
|
-
|
-
|
Reference price
2 |
52.68
|
148.6
|
146.8
|
58.95
|
21.40
|
17.42
|
17.42
|
17.42
|
Announcement Date
|
27/03/20
|
25/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
18.54
|
4,300
|
1,035
|
357.1
|
857.5
|
1,313
|
1,959
|
EBITDA
1 |
-177.5
|
-369.1
|
2,021
|
-993.4
|
-1,621
|
-159
|
132.6
|
838.2
|
EBIT
1 |
-200
|
-400.9
|
1,941
|
-1,181
|
-1,936
|
-393
|
-68.65
|
641.8
|
Operating Margin
|
-
|
-2,161.66%
|
45.14%
|
-114.12%
|
-542.3%
|
-45.83%
|
-5.23%
|
32.77%
|
Earnings before Tax (EBT)
1 |
-156.8
|
-396.6
|
1,937
|
-1,184
|
-1,932
|
-654
|
-445
|
-320
|
Net income
1 |
-156.8
|
-396.6
|
1,914
|
-909.4
|
-1,447
|
-610.5
|
-408.5
|
-320
|
Net margin
|
-
|
-2,138.9%
|
44.52%
|
-87.9%
|
-405.31%
|
-71.19%
|
-31.1%
|
-16.34%
|
EPS
2 |
-0.7041
|
-1.720
|
7.740
|
-3.680
|
-5.870
|
-1.422
|
-0.1456
|
1.372
|
Free Cash Flow
1 |
-280.2
|
-739.3
|
846.9
|
-2,927
|
-1,518
|
-599
|
-307
|
397
|
FCF margin
|
-
|
-3,986.61%
|
19.7%
|
-282.87%
|
-425.22%
|
-69.85%
|
-23.37%
|
20.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
41.9%
|
-
|
-
|
-
|
-
|
47.36%
|
FCF Conversion (Net income)
|
-
|
-
|
44.24%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.8000
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/03/20
|
25/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1,024
|
1,214
|
-
|
130.4
|
77.6
|
-
|
-
|
-
|
-
|
181.5
|
225.6
|
225.6
|
225.6
|
229.6
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
458.6
|
645.5
|
-
|
-
|
-
|
-507.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
44.77%
|
53.18%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-139.5
|
-701.9
|
-143.6
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
1.600
|
2.350
|
0.4900
|
-
|
-
|
-1.760
|
-0.5700
|
-2.840
|
-0.5800
|
-
|
-0.3259
|
-0.3259
|
-0.3259
|
-0.3098
|
-
|
Dividend per Share
2 |
-
|
0.8000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/10/21
|
25/02/22
|
28/04/22
|
08/09/22
|
28/10/22
|
27/02/23
|
28/04/23
|
30/08/23
|
30/10/23
|
23/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
588
|
4,304
|
4,614
|
-
|
-
|
216
|
870
|
933
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-280
|
-739
|
847
|
-2,927
|
-1,518
|
-599
|
-307
|
397
|
ROE (net income / shareholders' equity)
|
-15.9%
|
-10.5%
|
27.1%
|
-12.4%
|
-24.1%
|
-6.93%
|
-1.23%
|
6.63%
|
ROA (Net income/ Total Assets)
|
-12.2%
|
-9.3%
|
25.9%
|
-
|
-13.9%
|
-7.6%
|
-5.6%
|
-4.3%
|
Assets
1 |
1,290
|
4,266
|
7,383
|
-
|
10,394
|
8,033
|
7,295
|
7,442
|
Book Value Per Share
2 |
7.230
|
24.50
|
32.30
|
30.00
|
21.40
|
19.70
|
20.30
|
21.20
|
Cash Flow per Share
2 |
-0.8400
|
-2.030
|
8.290
|
-7.640
|
-3.680
|
-0.6900
|
0.3500
|
1.840
|
Capex
1 |
110
|
270
|
1,203
|
1,075
|
610
|
192
|
228
|
255
|
Capex / Sales
|
-
|
1,455.39%
|
27.98%
|
103.91%
|
170.87%
|
22.4%
|
17.34%
|
13.03%
|
Announcement Date
|
27/03/20
|
25/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Last Close Price
17.42
CNY Average target price
24.32
CNY Spread / Average Target +39.63% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.08% | 1.1B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.35B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|